| Biomarker ID | 964 |
| PMID | 22866141 |
| Year | 2011 |
| Biomarker | Soluble interleukin-6 Receptor (sIL-6R) |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score Upgrading Vs No Gleason Score Uprading |
| Type of Biomarker | Prognostic |
| Cohort | 51 patients with Prostate cancer were selected such that 24 had GS (5-6), 22 had GS 7 and 5 had GS (8-10) |
| Senstivity | 80% |
| Specificity | 76% |
| AUC | 0.8 |
| Accuracy | NA |
| Level Of Significance | p=0.024 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |